Oral Minocycline Challenge as a Potential First-line Therapy for Myalgic Encephalomyelitis and Long Covid-19 Syndrome
Chronic fatigue syndrome characterized by severe disabling fa tigue, prolonged post-exertional malaise, and unrefreshing sleep markedly reduces the activities of daily living and impairs the quality of life. Central nervous system dysfunction associated with myalgic encephalomyelitis (ME) has been postulated as the main cause of chronic fatigue syndrome. Recently, oral mino cycline therapy has been reported to exert favorable therapeutic effects in some patients with ME, especially in the initial stage of the disease, although many patients discontinued treatment in the first few days because of acute adverse effects such as nausea and/or dizziness.